Largest zinc-silver-lead target defined by Inca at Riqueza

|

Published 17-MAR-2017 14:53 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Shares in Inca Minerals (ASX:ICG) opened nearly 10% higher on Thursday morning after the company released some of its most promising exploration results to date.

It should be noted that share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.

Recently resumed mapping and sampling at the Riqueza project has resulted in the delineation of rich new forms of mineralisation, resulting in management taking the decision to extend the surface mapping and sampling program to other parts of the Humaspunco Hill. The drilling campaign will include these new targets.

The recent work has resulted in the identification of a large structure, the Callancocha Structure, as being a major new drill target. It is believed to be a feeder zone responsible for much of the Zn-Ag-Pb mineralisation at Humaspunco. It is a large project-scale fault comprising several mineralised veins, up to 5m thick. Importantly, mineralisation associated with it appears to continue unbroken into the adjacent cross-cutting EW veins and mantos.

Another mineralised structure has been recognised that runs perpendicularly to the Callancocha Structure. This fault is probably related to regional folding.

The occurrence of mineralised faults, mineralised breccia-faults and mineralised tension gashes strongly indicate that fluids bearing zinc, silver and lead were pumped into the limestone sequence when the faults were active.

The recent results are very positive says ICG’s Managing Director Ross Brown. “There are more mineralised structures, veins and breccias occurring at the surface at Humaspunco than previously indicated; that mineralisation now appears continuous between the Callancocha Structure and the EW veins and mantos and; that mineralisation is now believed linked to fault activity.

There is an expectation that because of this mineralisation at Humaspunco “we may see even more mineralisation continue at depth than we already see at surface” Mr Brown concludes.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X